Safety and Efficacy of Cisplatin Based Transarterial Chemo-Embolization in Combination with Gemcitabine and Cisplatin for Patients with Unresectable Cholangiocellular Carcinoma

Safety and Efficacy of Cisplatin Based Transarterial Chemo-Embolization in Combination with Gemcitabine and Cisplatin for Patients with Unresectable Cholangiocellular Carcinoma - Safety and Efficacy of Cisplatin Based Transarterial Chemo-Embolization in Combination with Gemcitabine and Cisplatin for Patients with Unresectable Cholangiocellular Carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004776

Enrollment

Registered

2010-12-22

Start date

2010-12-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocellular Carcinoma

Interventions

Cisplatin Based Transarterial Chemo-Embolization in Combination with Gemcitabine and Cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients aged 20 Years or over 2) Patients who were fully informed of the study beforehand and signed the informed consent to participate in the study 3) Patients diagnosed with typical cholangiocellular carcinoma by histologically proven and diagnostic imaging 4) Patients with tumor in the liver 5) Patients in whom complete resection of the tumor by hepatectomy cannot be expected to succeed. 6) Patients with an ECOG PS(Performance Status) Score of 0 or 1. 7) Patients who are expected to live more than 12 weeks. 8) Adequate organ function

Exclusion criteria

Exclusion criteria: 1) History of malignant tumor 2) Severe cardiac disease 3) Active infection 4) History of HIV infection 5) Renal dialysis 6) Intracranial tumor 7) Clinically uncontrolled ascites or pleural effusion 8) Clinically severe gastrointestinal bleeding within 4 weeks of the start of treatment 9) Prior history of chemotherapy with gemcitabine and cisplatin

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Overall Survival (OS) Progression Free Survival (PFS) 1-year Survival Rate 6 months Progression Free Survival Response Rate (RR)	—

Countries

Japan

Contacts

Public ContactSadahisa Ogasawara

Chiba University Hospital Department of Gastroenterology

ogasawaras@graduate.chiba-u.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026